Erectile dysfunction and treatment of carcinoma of the prostate

被引：6

作者：

Carson C.C. ^{[1
]}

Hubbard J.S. ^{[1
]}

Wallen E. ^{[1
]}

机构：

[1] Division of Urology, University of North Carolina, 2140 Bioinformatics Bldg CB 7235, Chapel Hill, 27599-7235, NC

来源：

Current Urology Reports | 2005年 / 6卷 / 6期

关键词：

Alprostadil; Erectile Dysfunction; Erectile Function; Radical Prostatectomy; Vardenafil;

D O I：

10.1007/s11934-005-0042-1

中图分类号：

学科分类号：

摘要：

Prostate cancer is the leading malignancy in men in the United States and causes more than 60,000 deaths annually. Treatment of prostate cancer, whether it be with surgery, radiation therapy, cryotherapy, or medical treatment, is associated with significant life-altering morbidity. Incontinence and erectile dysfunction (ED) too often are sequelae of these treatment alternatives. ED can be a significant complication and can alter the life of the patient with prostate cancer and his partner. Newer modifications of the radical prostatectomy with nerve-sparing techniques are the cornerstone of erection preservation. Time following radical prostatectomy has been shown to increase erectile function such that more patients have functional erections at 3 years than 1 year after surgery. With the advent of phosphodiesterase-5 (PDE-5) inhibitors, many men can have improved functional erections and return to active coitus. Prevention of ED also is an important management technique. Evidence is gathering that prophylaxis with regular vasoactive injection or daily PDE-5 agents may be an integral part of preservation of corpus cavernosum smooth muscle function. Combination medical therapy and surgical penile prosthesis implantation also are options for patients who do not respond to oral PDE-5 inhibitors. © 2005, Current Science Inc.

引用

页码：461 / 469

页数：8

共 52 条

[1]

Gray A., Feldman H.A., McKinlay J.B., Longcope C., Age, disease, and changing sex hormone levels in middle-aged men: results of the Massachusetts Male Aging Study, J Clin Endocrinol Metab, 73, pp. 1016-1025, (1991)

[2]

Quinlan D.M., Epstein J.I., Carter B.S., Walsh P.C., Sexual function following radical prostatectomy: influence of preservation of neurovascular bundles, J Urol, 145, pp. 998-1002, (1991)

[3]

Zisman A., Leibovici D., Kleinmann J., Et al., The impact of prostate biopsy on patient well-being: a prospective study of pain, anxiety, and erectile dysfunction, J Urol, 165, pp. 445-454, (2001)

[4]

Schover L.R., Fouladi R.T., Warneke C.L., Et al., The use of treatments for erectile dysfunction among survivors of prostate carcinoma, Cancer, 95, pp. 2397-2407, (2002)

[5]

User H.M., Hairston J.H., Zelner D.J., Et al., Penile weight and cell subtype specific changes in a post-radical prostatectomy model of erectile dysfunction, J Urol, 169, pp. 1175-1179, (2003)

[6]

Kim J.H., Carson C.C., Development of Peyronie’s disease with the use of a vacuum constriction device, J Urol, 149, pp. 1314-1315, (1993)

[7]

Schwartz E.J., Wong P., Graydon R.J., Sildenafil preserves intracorporeal smooth muscle after radical retropubic prostatectomy, J Urol, 171, pp. 771-774, (2004)

[8]

Nehra A., Pharmaco-angiographic prevalence of accessory pudendal arteries: role in maintaining sexual function following radical retropubic prostatectomy, J Urol, 157, (1997)

[9]

Mulhall J.P., Graydon R.J., The hemodynamics of erectile dysfunction following nerve-sparing radical retropubic prostatectomy, Int J Impot Res, 8, pp. 91-94, (1996)

[10]

Rogers C.G., Trock B.P., Walsh P.C., Preservation of accessory pudendal arteries during radical retropubic prostatectomy, Urology, 64, pp. 148-151, (2004)

← 1 2 3 4 5 6 →